Table 1.
Baseline demographic and clinical characteristics of all patients that underwent colonic or rectal resection for colorectal cancer (n = 415)
| Variable | All respondents (n = 415) | Right‐sided resection (n = 148) | Left‐sided resection (n = 147) | Rectal resection (n = 120) | p value |
|---|---|---|---|---|---|
| Age at baseline (years) | 0.003 | ||||
| ≤70 | 248 (59.8%) | 76 (51.4%) | 86 (58.5%) | 86 (71.7%) | |
| >70 | 167 (40.2%) | 72 (48.6%) | 61 (41.5%) | 34 (28.3%) | |
| Gender (male) | 249 (60.0%) | 85 (57.4%) | 89 (60.5%) | 75 (62.5%) | 0.692 |
| Time between diagnosis and baseline (days) | 21 [15–28] | 21 [15–27] | 19 [13–26] | 24 [18–35] | 0.008 |
| Highest level of educationa | 0.344 | ||||
| Low | 41(9.9%) | 12 (8.1%) | 18 (12.2%) | 11 (9.2%) | |
| Medium | 265 (63.9%) | 89 (60.1%) | 99 (67.3%) | 77 (64.2%) | |
| High | 105 (25.3%) | 44 (29.7%) | 30 (20.4%) | 31 (25.8%) | |
| Missing | 4 (1%) | 3 (2.0%) | 0 (0%) | 1 (0.8%) | |
| BMI (kg/m2) | 0.362 | ||||
| <25 | 147 (35.4%) | 53 (35.8%) | 47 (32.0%) | 47 (39.2%) | |
| 25−30 | 161 (38.8%) | 57 (38.5%) | 55 (37.4%) | 49 (40.8%) | |
| ≥30 | 102 (24.6%) | 35 (23.6%) | 44 (29.9%) | 23 (19.2%) | |
| Missing | 5 (1.2%) | 3 (2.0%) | 1 (0.7%) | 1 (0.8%) | |
| ASA grade | 0.055 | ||||
| I–II | 354 (85.3%) | 119 (80.4%) | 131 (89.1%) | 104 (86.7%) | |
| III–V | 58 (14%) | 29 (19.6%) | 16 (10.9%) | 13 (10.8%) | |
| Missing | 3 (0.7%) | 0 (0%) | 0 (0%) | 3 (2.5%) | |
| Smoking | 0.542 | ||||
| Current smoker | 45 (10.8%) | 18 (12.2%) | 12 (8.2%) | 15 (12.5%) | |
| Former smoker | 241 (58.1%) | 83 (56.1%) | 84 (57.1%) | 74 (61.7%) | |
| Non‐smoker | 118 (28.4%) | 43 (29.1%) | 46 (31.3%) | 29 (24.2%) | |
| Missing | 11 (2.7%) | 4 (2.7%) | 5 (3.4%) | 2 (1.7%) | |
| Number of comorbid conditions | 0.012 | ||||
| 0 | 116 (28%) | 29 (19.6%) | 50 (34.0%) | 37 (30.8%) | |
| 1 | 135 (32.5%) | 46 (31.1%) | 46 (31.3%) | 43 (35.8%) | |
| ≥2 | 162 (39%) | 73 (49.3%) | 50 (34.0%) | 39 (32.5%) | |
| Missing | 2 (0.5%) | 0 (0%) | 1 (0.7%) | 1 (0.8%) | |
| Tumor stage (pTNM) | 0.004 | ||||
| I | 126 (30.4%) | 48 (32.4%) | 47 (32.0%) | 31 (25.8%) | |
| II | 115 (27.7%) | 51 (34.5%) | 42 (28.6%) | 22 (18.3%) | |
| III | 157 (37.8%) | 44 (29.7%) | 53 (36.1%) | 60 (50.0%) | |
| IV | 10 (2.4%) | 1 (0.7%) | 4 (2.7%) | 5 (4.2%) | |
| Unknown | 7 (1.7%) | 4 (2.7%) | 1 (0.7%) | 2 (1.7%) | |
| (Neo)adjuvant therapy (yes) | 150 (36.1%) | 35 (23.6%) | 48 (32.7%) | 67 (55.8%) | <0.001 |
| Radiotherapy only | 29 (7.0%) | 0 (0%) | 0 (0%) | 29 (24.2%) | |
| Chemotherapy only | 88 (21.2%) | 33 (22.3%) | 48 (32.7%) | 7 (5.8%) | |
| Chemo and radiotherapy | 33 (8.0%) | 2 (1.4%) | 0 (0%) | 31 (25.8%) | |
| Surgical approach | 0.002 | ||||
| Laparoscopy | 381 (91.8%) | 139 (93.9%) | 142 (96.6%) | 100 (83.3%) | |
| Open | 25 (6.0%) | 8 (5.4%) | 5 (3.4%) | 12 (10.0%) | |
| TaTME | 4 (1.0%) | 0 (0%) | 0 (0%) | 4 (3.3%) | |
| Missing | 5 (1.2%) | 1 (0.7%) | 0 (0%) | 4 (3.4%) | |
| Stoma (yes) | 73 (17.6%) | 1 (0.7%) | 3 (2.1%) | 69 (57.5%) | <0.001 |
| Diverting | 47 (11.3%) | 0 (0%) | 1 (0.7%) | 46 (38.3%) | |
| End | 25 (6.0%) | 1 (0.7%) | 2 (1.4%) | 22 (18.3%) | |
| Unknown | 1 (0.2%) | 0 (0%) | 0 (0%) | 1 (0.8% | |
| Length of hospital stay | 0.090 | ||||
| <10 days | 357 (86.0%) | 134 (90.5%) | 127 (86.4%) | 96 (80.0%) | |
| ≥10 days | 39 (9.4%) | 11 (7.4%) | 11 (7.5%) | 17 (14.2%) | |
| Missing | 19 (4.6%) | 3 (2.0%) | 9 (6.1%) | 7 (5.8%) |
Note: Values are in numbers (percentages) or median [IQR].
Abbreviations: ASA, American Society of Anesthesiologists; BMI, body mass index; IQR, interquartile range; kg, kilograms; m, meters; pTNM, pathological tumor node and metastasis stage; TaTME, transanal total mesorectal excision.
a
Level of education: low (no or primary school); medium (lower general secondary education or vocational training); high (pre‐university education, high vocational training, university).